Cleveland Clinic executive considered for VA top job

Laura Pedulli | | Health Exec | Policy & Regulations

After a controversy of excessive wait times and IT struggles at the Department of Veterans Affairs spurred the resignation of Eric Shinseki, the White House now is considering a high profile hospital executive from Cleveland Clinic to take over the beleaguered agency, reports the Wall Street Journal.

The White House currently is considering nominating Delos “Toby” Cosgrove, MD, CEO and president of the Cleveland Clinic, to take the helm of the VA. Sources told the newspaper that he is seriously considering pursuing the position.

Cosgrove previously served as a surgeon in the U.S. Air Force and served in Da Nang, Vietnam. He was awarded the Bronze Star and the Republic of Vietnam Commendation Medal.

Laura Pedulli

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
10 signs AI is ‘eating the world (of venture capital)’
Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.